Autor: |
Masayuki, Watanabe, Yasushi, Toh, Ryu, Ishihara, Koji, Kono, Hisahiro, Matsubara, Tatsuya, Miyazaki, Masaru, Morita, Kentaro, Murakami, Kei, Muro, Hodaka, Numasaki, Tsuneo, Oyama, Hiroshi, Saeki, Koji, Tanaka, Takahiro, Tsushima, Masaki, Ueno, Takashi, Uno, Toshiyuki, Yoshio, Shiyori, Usune, Arata, Takahashi, Hiroaki, Miyata |
Rok vydání: |
2022 |
Zdroj: |
Esophagus : official journal of the Japan Esophageal Society. 20(1) |
ISSN: |
1612-9067 |
Popis: |
The registration committee for esophageal cancer in the Japan Esophageal Society (JES) has collected the patients' characteristics, treatment, and outcomes of patients who underwent any treatment during 2015 in Japan.We analyzed patients' data who had visited the participating hospitals in 2015. We collected the data using the National Clinical Database with a web-based data collection system. We used the Japanese Classification of Esophageal Cancer 10A total of 9368 cases were registered from 355 institutions in Japan. Squamous cell carcinoma and adenocarcinoma accounted for 86.7% and 7.4%, respectively. The 5-year survival rates of patients treated by endoscopic resection, concurrent chemoradiotherapy, radiotherapy alone, and esophagectomy were 87.2%, 33.5%, 24.2%, and 59.9%, respectively. Esophagectomy was performed in 5172 cases. Minimally invasive approaches were selected for 60.6%, and 54.4% underwent thoracoscopic esophagectomy. The operative mortality (within 30 days after surgery) was 0.79% and the hospital mortality was 2.3%. The survival curves showed an excellent discriminatory ability both in the clinical and pathologic stages by the JES system. The survival of pStage IV was better than IIIC in the UICC system because pStage IV included the patients with supraclavicular lymph node metastasis (M1 LYM).We hope this report improves all aspects of diagnosing and treating esophageal cancer in Japan. |
Databáze: |
OpenAIRE |
Externí odkaz: |
|